These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 32424350)

  • 1. Cas9 activates the p53 pathway and selects for p53-inactivating mutations.
    Enache OM; Rendo V; Abdusamad M; Lam D; Davison D; Pal S; Currimjee N; Hess J; Pantel S; Nag A; Thorner AR; Doench JG; Vazquez F; Beroukhim R; Golub TR; Ben-David U
    Nat Genet; 2020 Jul; 52(7):662-668. PubMed ID: 32424350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parallel CRISPR-Cas9 screens clarify impacts of p53 on screen performance.
    Bowden AR; Morales-Juarez DA; Sczaniecka-Clift M; Agudo MM; Lukashchuk N; Thomas JC; Jackson SP
    Elife; 2020 May; 9():. PubMed ID: 32441252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells.
    Ihry RJ; Worringer KA; Salick MR; Frias E; Ho D; Theriault K; Kommineni S; Chen J; Sondey M; Ye C; Randhawa R; Kulkarni T; Yang Z; McAllister G; Russ C; Reece-Hoyes J; Forrester W; Hoffman GR; Dolmetsch R; Kaykas A
    Nat Med; 2018 Jul; 24(7):939-946. PubMed ID: 29892062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR/Cas9 treatment causes extended TP53-dependent cell cycle arrest in human cells.
    Geisinger JM; Stearns T
    Nucleic Acids Res; 2020 Sep; 48(16):9067-9081. PubMed ID: 32687165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adding to the CASeload: unwarranted p53 signaling induced by Cas9.
    Rendo V; Enache OM; Ben-David U
    Mol Cell Oncol; 2020; 7(5):1789419. PubMed ID: 32944644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response.
    Haapaniemi E; Botla S; Persson J; Schmierer B; Taipale J
    Nat Med; 2018 Jul; 24(7):927-930. PubMed ID: 29892067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Editing of the
    Mirgayazova R; Khadiullina R; Chasov V; Mingaleeva R; Miftakhova R; Rizvanov A; Bulatov E
    Genes (Basel); 2020 Jun; 11(6):. PubMed ID: 32630614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the CRISPR/Cas9 directed mutant TP53 gene repairing effect in human prostate cancer cell line PC-3.
    Batır MB; Şahin E; Çam FS
    Mol Biol Rep; 2019 Dec; 46(6):6471-6484. PubMed ID: 31571107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roles of TP53 gene in the development of resistance to PI3K inhibitor resistances in CRISPR-Cas9-edited lung adenocarcinoma cells.
    Hou J; Cao X; Cheng Y; Wang X
    Cell Biol Toxicol; 2020 Oct; 36(5):481-492. PubMed ID: 32239370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cas9-nickase-mediated genome editing corrects hereditary tyrosinemia in rats.
    Shao Y; Wang L; Guo N; Wang S; Yang L; Li Y; Wang M; Yin S; Han H; Zeng L; Zhang L; Hui L; Ding Q; Zhang J; Geng H; Liu M; Li D
    J Biol Chem; 2018 May; 293(18):6883-6892. PubMed ID: 29507093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in
    Stolte B; Iniguez AB; Dharia NV; Robichaud AL; Conway AS; Morgan AM; Alexe G; Schauer NJ; Liu X; Bird GH; Tsherniak A; Vazquez F; Buhrlage SJ; Walensky LD; Stegmaier K
    J Exp Med; 2018 Aug; 215(8):2137-2155. PubMed ID: 30045945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restoring the p53 'Guardian' Phenotype in p53-Deficient Tumor Cells with CRISPR/Cas9.
    Chira S; Gulei D; Hajitou A; Berindan-Neagoe I
    Trends Biotechnol; 2018 Jul; 36(7):653-660. PubMed ID: 29478674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression.
    Thiem A; Hesbacher S; Kneitz H; di Primio T; Heppt MV; Hermanns HM; Goebeler M; Meierjohann S; Houben R; Schrama D
    J Exp Clin Cancer Res; 2019 Sep; 38(1):397. PubMed ID: 31506076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.
    Esfandiari A; Hawthorne TA; Nakjang S; Lunec J
    Mol Cancer Ther; 2016 Mar; 15(3):379-91. PubMed ID: 26832796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Manipulating plant RNA-silencing pathways to improve the gene editing efficiency of CRISPR/Cas9 systems.
    Mao Y; Yang X; Zhou Y; Zhang Z; Botella JR; Zhu JK
    Genome Biol; 2018 Sep; 19(1):149. PubMed ID: 30266091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep).
    Cheng LL; Itahana Y; Lei ZD; Chia NY; Wu Y; Yu Y; Zhang SL; Thike AA; Pandey A; Rozen S; Voorhoeve PM; Yu Q; Tan PH; Bay BH; Itahana K; Tan P
    Clin Cancer Res; 2012 Aug; 18(15):4201-12. PubMed ID: 22675170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells.
    Menendez JA; Lupu R
    Int J Mol Med; 2005 Jan; 15(1):33-40. PubMed ID: 15583825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)/CRISPR-Associated Endonuclease Cas9-Mediated Homology-Independent Integration for Generating Quality Control Materials for Clinical Molecular Genetic Testing.
    Lin G; Zhang K; Peng R; Han Y; Xie J; Li J
    J Mol Diagn; 2018 May; 20(3):373-380. PubMed ID: 29680088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types.
    Parikh N; Hilsenbeck S; Creighton CJ; Dayaram T; Shuck R; Shinbrot E; Xi L; Gibbs RA; Wheeler DA; Donehower LA
    J Pathol; 2014 Apr; 232(5):522-33. PubMed ID: 24374933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene expression profiles modulated by the human carcinogen aristolochic acid I in human cancer cells and their dependence on TP53.
    Simões ML; Hockley SL; Schwerdtle T; Gamboa da Costa G; Schmeiser HH; Phillips DH; Arlt VM
    Toxicol Appl Pharmacol; 2008 Oct; 232(1):86-98. PubMed ID: 18639569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.